Stoke Therapeutics (NASDAQ:STOK) Trading 7.2% Higher

Stoke Therapeutics, Inc. (NASDAQ:STOK) was up 7.2% during trading on Wednesday . The company traded as high as $16.49 and last traded at $16.46. Approximately 277,244 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 932,838 shares. The stock had previously closed at $15.35.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on STOK. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 6th. Canaccord Genuity Group reduced their target price on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.57.

Stoke Therapeutics Stock Performance

The firm’s 50-day simple moving average is $11.75 and its 200-day simple moving average is $7.46. The company has a market capitalization of $751.05 million, a price-to-earnings ratio of -6.17 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million. Equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.31 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at $126,550.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Insiders sold 3,622,741 shares of company stock valued at $41,935,115 in the last ninety days. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System acquired a new position in Stoke Therapeutics in the first quarter valued at about $141,000. Dorsey & Whitney Trust CO LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $43,000. Sherbrooke Park Advisers LLC bought a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $48,000. BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after buying an additional 6,636 shares during the period. Finally, Corton Capital Inc. bought a new position in Stoke Therapeutics in the third quarter valued at approximately $58,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.